NFL Biosciences SA (ALNFL.PA)
EUR 1.88
(-2.59%)
EUR 1.88
(-2.59%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.43 Million EUR | -43.7% |
| 2022 | -3.08 Million EUR | -241.87% |
| 2021 | -901.86 Thousand EUR | -183.58% |
| 2020 | -318.02 Thousand EUR | 8.43% |
| 2019 | -347.29 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -896.06 Thousand EUR | 54.12% |
| 2023 FY | -4.43 Million EUR | -43.7% |
| 2023 Q4 | -1.95 Million EUR | 21.15% |
| 2023 Q2 | -2.47 Million EUR | -42.44% |
| 2022 Q4 | -1.73 Million EUR | -36.47% |
| 2022 FY | -3.08 Million EUR | -241.87% |
| 2022 Q2 | -1.27 Million EUR | 0.0% |
| 2021 FY | -901.86 Thousand EUR | -183.58% |
| 2021 Q2 | -221.05 Thousand EUR | 0.0% |
| 2020 FY | -318.02 Thousand EUR | 8.43% |
| 2019 FY | -347.29 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -29.848% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 96.522% |
| Adocia SA | -17.62 Million EUR | 74.859% |
| Aelis Farma SA | -6.46 Million EUR | 31.428% |
| Biophytis S.A. | -14.33 Million EUR | 69.089% |
| Advicenne S.A. | -6.45 Million EUR | 31.386% |
| genOway Société anonyme | 2.06 Million EUR | 314.517% |
| IntegraGen SA | -183.77 Thousand EUR | -2310.851% |
| Medesis Pharma S.A. | -4.22 Million EUR | -4.754% |
| Neovacs S.A. | -6.9 Million EUR | 35.861% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -469.289% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -41.22% |
| Sensorion SA | -22.31 Million EUR | 80.142% |
| Theranexus Société Anonyme | -7.64 Million EUR | 42.038% |
| TME Pharma N.V. | -5.62 Million EUR | 21.223% |
| Valbiotis SA | -7.16 Million EUR | 38.123% |
| TheraVet SA | -2.17 Million EUR | -103.687% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 78.162% |
| argenx SE | -417.15 Million EUR | 98.938% |
| BioSenic S.A. | -7.04 Million EUR | 37.068% |
| Celyad Oncology SA | -8.45 Million EUR | 47.612% |
| DBV Technologies S.A. | -85.24 Million EUR | 94.803% |
| Galapagos NV | -88.26 Million EUR | 94.98% |
| Genfit S.A. | -26.58 Million EUR | 83.332% |
| GeNeuro SA | -14.35 Million EUR | 69.142% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 72.298% |
| Innate Pharma S.A. | -12.66 Million EUR | 65.029% |
| Inventiva S.A. | -102.7 Million EUR | 95.686% |
| MaaT Pharma SA | -19.94 Million EUR | 77.785% |
| MedinCell S.A. | -20.97 Million EUR | 78.88% |
| Nanobiotix S.A. | -26.77 Million EUR | 83.456% |
| Onward Medical N.V. | -35.46 Million EUR | 87.507% |
| Oryzon Genomics S.A. | -4.54 Million EUR | 2.611% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 80.726% |
| Oxurion NV | -12.11 Million EUR | 63.415% |
| Pharming Group N.V. | -4.87 Million EUR | 9.204% |
| Poxel S.A. | -28.76 Million EUR | 84.597% |
| GenSight Biologics S.A. | -29.69 Million EUR | 85.081% |
| Transgene SA | -30.01 Million EUR | 85.238% |
| Financière de Tubize SA | -2.14 Million EUR | -106.645% |
| UCB SA | 604 Million EUR | 100.734% |
| Valneva SE | -82.08 Million EUR | 94.603% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 84.636% |